A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
NCT07561814 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1030
Last updated 2026-05-01
Summary
The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress.
The main questions it aims to answer are:
* Can combining these types of data more accurately estimate how long a person might survive?
* Can it better predict the risk of the cancer coming back?
Participants will not have any extra tests or treatments. They will:
* Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results)
* Receive a follow-up phone call about every 3 months for up to 3 years to share health updates
Conditions
Sponsors & Collaborators
-
The First Affiliated Hospital of University of South China
collaborator OTHER -
First Affiliated Hospital Xi'an Jiaotong University
collaborator OTHER -
Shanghai Zhongshan Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-08
- Primary Completion
- 2029-07-31
- Completion
- 2029-12-31
Countries
- China
Study Locations
More Related Trials
-
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
NCT04281511 ·Status: COMPLETED
-
Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center
NCT05141656 ·Status: UNKNOWN
-
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
NCT07448376 ·Status: NOT_YET_RECRUITING
-
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
NCT05621824 ·Status: NOT_YET_RECRUITING
-
Biomarkers Study in Pancreatic Cancer
NCT01666184 ·Status: UNKNOWN
-
Bioinformation Therapy for Pancreatic Cancer
NCT03239184 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
NCT02023021 ·Status: COMPLETED ·Phase: PHASE2
-
Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer
NCT05201729 ·Status: UNKNOWN
-
Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx
NCT00767273 ·Status: COMPLETED ·Phase: NA
-
Multimodal Therapy Impact on Pancreatic Cancer Survival
NCT06938906 ·Status: ACTIVE_NOT_RECRUITING
-
Role of Perfusion CT in Pancreatic Cancer
NCT01703650 ·Status: UNKNOWN
-
Studying Biomarkers in Patients With Pancreatic Cancer
NCT00900003 ·Status: COMPLETED
-
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
NCT06873178 ·Status: ACTIVE_NOT_RECRUITING
-
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
NCT05287347 ·Status: WITHDRAWN
-
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
NCT01692873 ·Status: COMPLETED ·Phase: NA
-
A CT-based Radiomics Model to Predict Survival-graded Fibrosis in PDAC
NCT06267690 ·Status: COMPLETED
-
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
NCT06307080 ·Status: RECRUITING ·Phase: NA
-
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
NCT04902261 ·Status: UNKNOWN ·Phase: PHASE2
-
Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer
NCT04110769 ·Status: UNKNOWN ·Phase: NA
-
Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
NCT04466189 ·Status: ENROLLING_BY_INVITATION
-
Influence of Metastatic Sites on Survival Outcomes and Predictive Factors for Extended Survival in Metastatic Pancreatic Cancer a Retrospective Study
NCT07086352 ·Status: NOT_YET_RECRUITING
-
Early Detection of Pancreatic Cancer
NCT05596435 ·Status: UNKNOWN
-
Personalized Precision Diagnosis and Treatment of Pancreatic Cancer
NCT04373928 ·Status: UNKNOWN ·Phase: NA
-
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
NCT05547074 ·Status: COMPLETED
-
Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer
NCT02685228 ·Status: UNKNOWN ·Phase: NA